ITUA20161679A1 - Composizione per prevenire e trattare patologie neurodegenerative e disturbi cognitivi - Google Patents

Composizione per prevenire e trattare patologie neurodegenerative e disturbi cognitivi

Info

Publication number
ITUA20161679A1
ITUA20161679A1 ITUA2016A001679A ITUA20161679A ITUA20161679A1 IT UA20161679 A1 ITUA20161679 A1 IT UA20161679A1 IT UA2016A001679 A ITUA2016A001679 A IT UA2016A001679A IT UA20161679 A ITUA20161679 A IT UA20161679A IT UA20161679 A1 ITUA20161679 A1 IT UA20161679A1
Authority
IT
Italy
Prior art keywords
composition
prevent
cognitive disorders
treat neurodegenerative
neurodegenerative pathologies
Prior art date
Application number
ITUA2016A001679A
Other languages
English (en)
Inventor
Marco Marchetti
Francesco Bellini
Paolo Carboni
Original Assignee
Neuraxpharm Italy S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56203718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ITUA20161679(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuraxpharm Italy S P A filed Critical Neuraxpharm Italy S P A
Priority to ITUA2016A001679A priority Critical patent/ITUA20161679A1/it
Priority to ES17161008T priority patent/ES2933800T3/es
Priority to EP17161008.2A priority patent/EP3219306B1/en
Publication of ITUA20161679A1 publication Critical patent/ITUA20161679A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/70—Vitamins
    • A23V2250/712—Vitamin E
ITUA2016A001679A 2016-03-15 2016-03-15 Composizione per prevenire e trattare patologie neurodegenerative e disturbi cognitivi ITUA20161679A1 (it)

Priority Applications (3)

Application Number Priority Date Filing Date Title
ITUA2016A001679A ITUA20161679A1 (it) 2016-03-15 2016-03-15 Composizione per prevenire e trattare patologie neurodegenerative e disturbi cognitivi
ES17161008T ES2933800T3 (es) 2016-03-15 2017-03-15 Composición que comprende citicolina y homotaurina para la prevención y el tratamiento de enfermedades neuodegenerativas y trastornos cognitivos
EP17161008.2A EP3219306B1 (en) 2016-03-15 2017-03-15 Composition comprising citicoline and homotaurine for preventing and treating neuodegenerative diseases and cognitive disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITUA2016A001679A ITUA20161679A1 (it) 2016-03-15 2016-03-15 Composizione per prevenire e trattare patologie neurodegenerative e disturbi cognitivi

Publications (1)

Publication Number Publication Date
ITUA20161679A1 true ITUA20161679A1 (it) 2017-09-15

Family

ID=56203718

Family Applications (1)

Application Number Title Priority Date Filing Date
ITUA2016A001679A ITUA20161679A1 (it) 2016-03-15 2016-03-15 Composizione per prevenire e trattare patologie neurodegenerative e disturbi cognitivi

Country Status (3)

Country Link
EP (1) EP3219306B1 (it)
ES (1) ES2933800T3 (it)
IT (1) ITUA20161679A1 (it)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2912611C (en) 2015-11-18 2024-01-30 Fb Health S.P.A. Homotaurine compounds, compositions and formulations for animal care
WO2022157798A1 (en) * 2021-01-22 2022-07-28 Celagenex Research (India) Pvt. Ltd. Synergistic nutritional compositions for treating neurocognitive disorders

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015835A (en) * 1996-03-26 2000-01-18 Meddiss, Incorporated Methods of inducing analgesia or anesthesia and treating or preventing ischemic injury of tissues in general
US20030114415A1 (en) * 2001-12-14 2003-06-19 Wurtman Richard J. Compositions and methods for treating and preventing memory impairment using citicoline
WO2007049098A2 (en) * 2004-06-18 2007-05-03 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
US20100130537A1 (en) * 2007-04-26 2010-05-27 Eisai R&D Management Co., Ltd Cinnamide compounds for dementia
US20120316128A1 (en) * 2010-02-22 2012-12-13 Cristiano Virno Citicoline for the treatment of glaucoma and ocular hypertension

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1585520A1 (en) 2002-12-24 2005-10-19 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
ITUB20153066A1 (it) 2015-08-11 2017-02-11 Graal S R L Composizione alimentare e/o nutraceutica contenente pea

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015835A (en) * 1996-03-26 2000-01-18 Meddiss, Incorporated Methods of inducing analgesia or anesthesia and treating or preventing ischemic injury of tissues in general
US20030114415A1 (en) * 2001-12-14 2003-06-19 Wurtman Richard J. Compositions and methods for treating and preventing memory impairment using citicoline
WO2007049098A2 (en) * 2004-06-18 2007-05-03 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
US20100130537A1 (en) * 2007-04-26 2010-05-27 Eisai R&D Management Co., Ltd Cinnamide compounds for dementia
US20120316128A1 (en) * 2010-02-22 2012-12-13 Cristiano Virno Citicoline for the treatment of glaucoma and ocular hypertension

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JUDES POIRIER ET AL: "Pharmacogenomics and the Treatment of Sporadic Alzheimers Disease:A Decade of Progress", CURRENT PHARMACOGENOMICS AND PERSONALIZED MEDICINE, 1 March 2008 (2008-03-01), pages 63 - 76, XP055315182, Retrieved from the Internet <URL:http://adgen.myasustor.com/index_htm_files/Current%20Pharmacogen%20Pers%20Med%206_63.pdf> [retrieved on 20161028], DOI: 10.2174/187569208784017494 *

Also Published As

Publication number Publication date
ES2933800T3 (es) 2023-02-14
EP3219306B1 (en) 2022-11-16
EP3219306A1 (en) 2017-09-20

Similar Documents

Publication Publication Date Title
IL273693A (en) Treatment of inflammatory disorders
IL285151A (en) Methods for the treatment of fgf21-related disorders
DK3185876T3 (da) Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser
DK3307262T3 (da) Forbindelser til anvendelse ved behandling af neuromuskulære lidelser
IL262852A (en) Complement-mediated treatment of disorders
GB201411241D0 (en) Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201516905D0 (en) Treatment of Neurodegenerative diseases
DK3192524T3 (da) Hgf præparat egnet til behandling af neurologiske lidelser
GB201513845D0 (en) Neurodegenerative disorders
DK3200828T3 (da) Intranasale sammensætninger til behandling af neurologiske og neurodegenerative sygdomme og forstyrrelser
GB201612043D0 (en) Composition for treatment of disorders
RS64160B1 (sr) Kompozicije za čišćenje debelog creva i lečenje gastrointestinalnih poremećaja
IL263080B (en) Treatment of neurological disorders
GB201607388D0 (en) Treatment of impulsivity-related disorders
ITUA20161679A1 (it) Composizione per prevenire e trattare patologie neurodegenerative e disturbi cognitivi
DK3448382T3 (da) Arimoclomol til behandling af glucocerebrosidase-associerede lidelser
SG10201913129QA (en) Treatment and diagnosis of inflammatory disorders
GB201411616D0 (en) Diagnosis and treatment of neurodegenerative disorders
MA54630A (fr) N,n-bis-2-mercaptoéthyle isophtalamide pour le traitment des maladies neurodégénératives
BR112016028653A2 (pt) métodos de tratamento de doenças e distúrbios neurodesenvolvimentais
IL234962A0 (en) Use of substances to treat fat-related diseases
DK3442537T3 (da) (+)-azasetron til anvendelse i behandlingen af ørelidelser
GB201701455D0 (en) Neurodegenerative disorders
GB201602784D0 (en) New treatment of CFTR-related disorders
GB201516418D0 (en) Treatment of acute inflammatory disorders